NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - NYSE:NMR - US65535H2085 - ADR
7.47 USD
-0.09 (-1.19%)
7.47 USD
0 (0%)
Overall NMR gets a fundamental rating of 3 out of 10. We evaluated NMR against 236 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year NMR was profitable.
NMR had a negative operating cash flow in the past year.
NMR had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
NMR has a Return On Assets of 0.60%. This is in the lower half of the industry: NMR underperforms 69.33% of its industry peers.
NMR has a Return On Equity of 9.82%. This is comparable to the rest of the industry: NMR outperforms 56.72% of its industry peers.
NMR's Return On Invested Capital of 0.63% is on the low side compared to the rest of the industry. NMR is outperformed by 71.01% of its industry peers.
NMR had an Average Return On Invested Capital over the past 3 years of 0.42%. This is significantly below the industry average of 7.59%.
The 3 year average ROIC (0.42%) for NMR is below the current ROIC(0.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.63% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
NMR has a worse Profit Margin (7.19%) than 63.87% of its industry peers.
In the last couple of years the Profit Margin of NMR has declined.
The Operating Margin of NMR (9.96%) is worse than 68.49% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a Gross Margin of 39.95%. This is in the lower half of the industry: NMR underperforms 63.45% of its industry peers.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
The number of shares outstanding for NMR has been reduced compared to 5 years ago.
The debt/assets ratio for NMR has been reduced compared to a year ago.
2.2 Solvency
NMR has an Altman-Z score of -0.27. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.27, NMR is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
NMR has a Debt/Equity ratio of 10.44. This is a high value indicating a heavy dependency on external financing.
NMR has a worse Debt to Equity ratio (10.44) than 89.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.27 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.22 indicates that NMR may have some problems paying its short term obligations.
The Current ratio of NMR (0.22) is worse than 87.39% of its industry peers.
NMR has a Quick Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a Quick ratio of 0.22. This is amonst the worse of the industry: NMR underperforms 86.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 79.28% over the past year.
The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
NMR shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
Measured over the past years, NMR shows a quite strong growth in Revenue. The Revenue has been growing by 19.39% on average per year.
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
3.2 Future
The Earnings Per Share is expected to grow by 0.23% on average over the next years.
The Revenue is expected to decrease by -6.34% on average over the next years.
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue Next Year-21.32%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NMR is valuated reasonably with a Price/Earnings ratio of 8.30.
Compared to the rest of the industry, the Price/Earnings ratio of NMR indicates a rather cheap valuation: NMR is cheaper than 81.93% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.38. NMR is valued rather cheaply when compared to this.
NMR is valuated reasonably with a Price/Forward Earnings ratio of 9.44.
Based on the Price/Forward Earnings ratio, NMR is valued a bit cheaper than 77.31% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.86. NMR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.3 | ||
| Fwd PE | 9.44 |
4.2 Price Multiples
NMR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NMR is cheaper than 70.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.85 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.76
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 3.92%.
Compared to an average industry Dividend Yield of 8.21, NMR has a dividend in line with its industry peers.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.92% |
5.2 History
On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
NMR has paid a dividend for at least 10 years, which is a reliable track record.
NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
33.03% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
The dividend of NMR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.03%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
7.47
-0.09 (-1.19%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner Change4.93%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.91B
Analysts73.33
Price Target7.73 (3.48%)
Short Float %0.07%
Short Ratio3.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.92% |
Yearly Dividend0.27
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.65%
PT rev (3m)6.86%
EPS NQ rev (1m)-0.18%
EPS NQ rev (3m)177.61%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)3.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.11%
Revenue NY rev (3m)-18.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.3 | ||
| Fwd PE | 9.44 | ||
| P/S | 0.69 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.93 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | 22.85 |
EPS(TTM)0.9
EY12.05%
EPS(NY)0.79
Fwd EY10.59%
FCF(TTM)-3.56
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS10.9
BVpS7.99
TBVpS7.82
PEG (NY)N/A
PEG (5Y)0.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.65% | ||
| ROIC | 0.63% | ||
| ROICexc | 0.69% | ||
| ROICexgc | 0.7% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexcg growth 3Y16.87%
ROICexcg growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | 0.16 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -0.27 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
Revenue Next Year-21.32%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year20384.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A